See the difference between your comment on my factual post and pfeifers -
"I don't think we've been in such a position (remainong capital/high expenditure) before, therefore this I believe marks the first time for the auditor to make such statement."
You
"This is relatively standard in the biotech sector. Nothing unusual at all IMO."
Screenshot(s) from Annual Report of 29 Aug 24, page-14
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
-0.005(2.44%) |
Mkt cap ! $36.11M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 20.0¢ | 19.0¢ | $19.42K | 101.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8208 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 9829 | 1 |
View Market Depth
| Last trade - 15.42pm 03/09/2024 (20 minute delay) ? |
| CYP (ASX) Chart |